Literature DB >> 2571084

Clinical implications of positive tests for antibodies to human immunodeficiency virus type 1 in asymptomatic blood donors.

S F Leitman1, H G Klein, J J Melpolder, E J Read, J I Esteban, E M Leonard, L Harvath, J W Shih, R Nealon, J Foy.   

Abstract

Of 693,000 volunteer blood donors in Washington, D.C., who were screened for infection with human immunodeficiency virus type 1 (HIV-1) from July 1985 through December 1988, 284 tested positive on both enzyme immunoassay and Western blot assay. To determine the clinical importance of confirmed positive test results in asymptomatic blood donors, we followed 156 donors with positive Western blot assays and 80 donors with positive enzyme immunoassays but negative or indeterminate Western blots at 6-month intervals for a mean of 28 months. As compared with Western blot-negative persons, those with positive Western blots were significantly more likely to be black, male, and first-time donors and to have a history of venereal disease, generalized lymphadenopathy on examination, CD4-cell counts lower than 0.4 x 10(9) per liter, IgG levels higher than 18 g per liter, and antibody to hepatitis B core antigen on initial evaluation. In 17 (11 percent) of the Western blot-positive donors, the disease progressed to Class IV (symptomatic disease), according to the Centers for Disease Control system. CD4 counts below 0.2 x 10(9) per liter, IgA levels above 4 g per liter, abnormal proliferative responses to tetanus toxoid, and positive viral cultures were the strongest predictors of disease progression. Among the 80 donors with repeatedly reactive assay results but either negative or indeterminate Western blot assays, there was no evidence of HIV exposure in their histories, physical examinations, or laboratory evaluations, and manifestations of HIV infection developed in none of them. We conclude that a small number of persons with HIV infection continue to donate blood, despite attempts to exclude them, but that donors who test positive on enzyme immunoassay but persistently negative or indeterminate on Western blot assay probably do not represent a risk for the transmission of HIV.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2571084     DOI: 10.1056/NEJM198910053211401

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  9 in total

1.  Indeterminate HIV-1 western blots: implications and considerations for widespread HIV testing.

Authors:  C L Celum; R W Coombs
Journal:  J Gen Intern Med       Date:  1992 Nov-Dec       Impact factor: 5.128

2.  Markers for HIV-disease progression in untreated patients and patients receiving AZT: evaluation of viral activity, AZT resistance, serum cholesterol, beta 2-microglobulin, CD4+ cell counts, and HIV antigen.

Authors:  H Rübsamen-Waigmann; B Schröder; L Biesert; C D Bauermeister; H von Briesen; H Suhartono; F Zimmermann; H D Brede; A Regeniter; S Gerte
Journal:  Infection       Date:  1991       Impact factor: 3.553

3.  Synthetic-peptide-based enzyme-linked immunosorbent assay for screening human serum or plasma for antibodies to human immunodeficiency virus type 1 and type 2.

Authors:  L Gonzalez; R W Boyle; M Zhang; J Castillo; S Whittier; P Della-Latta; L M Clarke; J R George; X Fang; J G Wang; B Hosein; C Y Wang
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

4.  A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries.

Authors:  B Leese; J Hutton; A Maynard
Journal:  Pharmacoeconomics       Date:  1992-05       Impact factor: 4.981

Review 5.  Laboratory tests for detection of human immunodeficiency virus type 1 infection.

Authors:  N F Nuwayhid
Journal:  Clin Diagn Lab Immunol       Date:  1995-11

6.  Indeterminate western blot patterns in a cohort of individuals at high risk for human immunodeficiency virus (HIV-1) exposure.

Authors:  R T Davey; L R Deyton; J A Metcalf; M Easter; J A Kovacs; M Vasudevachari; M Psallidopoulos; L M Thompson; J Falloon; M A Polis
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

7.  Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation.

Authors:  A Shirai; M Cosentino; S F Leitman-Klinman; D M Klinman
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

8.  A Systematic Review of Interventions Used to Increase Blood Donor Compliance with Deferral Criteria.

Authors:  Julia C Cutts; Brendan Quinn; Clive R Seed; George Kotsiou; Ruth Pearson; Nick Scott; David P Wilson; Mary Ellen Harrod; Lisa Maher; Sharon Caris; Alex J Thompson; Michael Farrell; Joanne Pink; Margaret E Hellard
Journal:  Transfus Med Hemother       Date:  2020-07-23       Impact factor: 3.747

9.  Comparison of deferral rates using a computerized versus written blood donor questionnaire: a randomized, cross-over study [ISRCTN84429599].

Authors:  John W Sellors; Robert Hayward; Graham Swanson; Anita Ali; R Brian Haynes; Ronald Bourque; Karen-Ann Moore; Lynne Lohfeld; Dawn Dalby; Michelle Howard
Journal:  BMC Public Health       Date:  2002-08-21       Impact factor: 3.295

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.